Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Nelson

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Oncotarget|March 1, 2018
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse modelKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
American Journal of Clinical Oncology|April 18, 2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue SarcomasJoseph Daniel Pennington, Fritz C Eilber, Frederick R Eilber, et al.
Signal Transduction and Targeted Therapy|May 2, 2018
Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapyKentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Annals of Surgical Oncology|December 29, 2022
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal LiposarcomaMark A Eckardt, Danielle S Graham, Kyle D Klingbeil, et al.
Heliyon|July 14, 2018
Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutationsKentaro Miyake, Kei Kawaguchi, Masuyo Miyake, et al.
Oncotarget|December 22, 2017
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapyKentaro Miyake, Takashi Murakami, Tasuku Kiyuna, et al.
Tissue & Cell|October 13, 2018
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP)Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Oncotarget|March 1, 2018
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse modelKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
American Journal of Clinical Oncology|April 18, 2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue SarcomasJoseph Daniel Pennington, Fritz C Eilber, Frederick R Eilber, et al.
Signal Transduction and Targeted Therapy|May 2, 2018
Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapyKentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Annals of Surgical Oncology|December 29, 2022
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal LiposarcomaMark A Eckardt, Danielle S Graham, Kyle D Klingbeil, et al.
Heliyon|July 14, 2018
Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutationsKentaro Miyake, Kei Kawaguchi, Masuyo Miyake, et al.
Oncotarget|December 22, 2017
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapyKentaro Miyake, Takashi Murakami, Tasuku Kiyuna, et al.
Tissue & Cell|October 13, 2018
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP)Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Pageof 20